Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: A retrospective study  by Lin, Kuan-Hsiang et al.
Available online at www.sciencedirect.comScienceDirect
Journal of the Chinese Medical Association 77 (2014) 10e15
www.jcma-online.comOriginal Article
Efficacy, safety, and predictors of response to botulinum toxin type A in
refractory chronic migraine: A retrospective study
Kuan-Hsiang Lin a,b,c, Shih-Pin Chen b,c, Jong-Ling Fuh b,c, Yen-Feng Wang b,c,
Shuu-Jiun Wang b,c,d,*
aDepartment of Medicine, Taipei Veterans General Hospital, Taoyuan Branch, Taoyuan, Taiwan, ROC
b School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC
cDepartment of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
d Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan, ROC
Received January 10, 2013; accepted April 16, 2013AbstractBackground: Due to its persistent and debilitating nature, refractory chronic migraine (RCM) can cause significant socioeconomic burden. This
study retrospectively reviewed the efficacy and safety of botulinum toxin type A (BoNT-A) in the treatment of RCM. Predictors of treatment
response were also investigated.
Methods: We enrolled 94 patients in this study after reviewing the records of those patients who received BoNT-A injections 75 U in our
headache clinic, and who fulfilled the criteria for RCM established by Schulman et al. The outcome variables included headache frequency,
migraine disability assessment score, and adverse events recorded in headache diaries. Treatment response was defined as 30% reduction in
headache frequency from baseline at 12 weeks. Potential predictors of treatment response were evaluated, including patient demographics,
headache directionality, ocular-type headache, medication overuse, BoNT-A dosage, body mass index, and Beck depression inventory score.
Results: For the 94 patients with RCM who were enrolled, their mean baseline headache frequency was 23.9 days/28 days. At 12 weeks after
BoNT-A injection, the mean reduction in headache frequency was 6.5 days/28 days ( p < 0.001), and the median migraine disability assessment
score decreased from 60.0 to 30.0 ( p < 0.001). Thirty-seven (39.4%) patients responded to treatment, and only ocular-type headache was
associated with a higher response rate (ocular vs. nonocular, 54.8% vs. 31.7%; p ¼ 0.031). The most common adverse event was lateral eyebrow
elevation (19.1%), followed by neck soreness (5.3%).
Conclusion: About 40% of patients with RCM obtained 30% reduction in headache frequency at 12 weeks after BoNT-A injection, and
treatment-related adverse events were transient and acceptable. Ocular-type headache may predict treatment response.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Chronic migraine (CM) is a disabling headache disorder
affecting 1.4e2.2% of the general population,1e3 causing
significant disability and negatively impacting quality of
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http://dx.doi.org/10.1016/j.jcma.2013.09.006International Classification of Headache Disorders, 2nd Edi-
tion (ICHD-2),7 and subsequent revised criteria (ICHD-2R)
for CM specify that affected patients have headaches on 15
days/month for 3 months, with headaches occurring on 8
days classified as migraines, or responsive to migraine-
specific medications.7,8 Patients with CM generally have un-
satisfactory responses to abortive or preventative treat-
ments;3,9 headaches fail to respond to any adequate
pharmaceutical intervention in a subset of these patients, who
are classified as having refractory CM (RCM). This conditionhinese Medical Association. All rights reserved.
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posed diagnostic criteria (Table 1). RCM causes more sig-
nificant disability and socioeconomic burdens than CM, and
the development of an effective treatment for patients with
this condition is crucial.
Recently, botulinum toxin type A (BoNT-A) and topiramate
have been proven to be beneficial for CM prophylaxis,14e17
but their efficacy for RCM needs to be examined. In addi-
tion to evaluating the effectiveness and safety of BoNT-A
injection in patients with RCM, this study also aimed to
investigate possible predictors of treatment response.
2. Methods2.1. Clinical settingTaipei Veterans General Hospital is a 3015-bed tertiary
medical center serving veterans and nonveteran citizens, and
the hospital’s headache clinic has been operating since 1997.
Taiwan’s National Health Insurance (NHI) Program was
launched in 1995 and covered >99% of the population in
2008. Patients can choose to visit any hospital or physician,
regardless of illness severity.
When visiting our headache clinic, all patients completed a
structured headache questionnaire and were instructed to keep
a headache diary in order to obtain accurate headache infor-
mation and evaluate treatment response. Patients with CM
were given the option of BoNT-A injection, and the decision to
undergo this treatment depended on each patient’s willingness
and the ability to cover treatment costs. Because BoNT-A is
not covered by the NHI in Taiwan and the price is high (>20-
fold higher than a regular clinic visit), patients tended to select
BoNT-A injection only when their headaches were refractory
to all oral medications. A written informed consent for BoNT-
A injection was obtained from each patient prior to the in-
jection because this medication was not indicated for treat-
ment of chronic migraine.
This retrospective review was approved by the Institutional
Review Board (IRB) of Taipei Veterans General Hospital (Tai-
pei, Taiwan).Table 1
Proposed criteria for refractory chronic migraine.
1. Patient has diagnosis of chronic migraine (or migraine)
2. Patient has failed adequate trial of at least two of the following four drug
classes
A. Anticonvulsants
B. Beta blockers
C. Tricyclics
D. Calcium channel blockers
3. Patient has modified lifestyle and eliminated triggers
4. Patient has failed abortive medications, including
A. Triptans and DHE
B. NSAIDs and combination analgesics
5. Modifiers may be present:
A. With or without medication overuse
B. With significant disability
DHE ¼ dihydroergotamine; NSAIDs ¼ nonsteroidal anti-inflammatory drugs.2.2. PatientsThe medical records, headache questionnaires, and diaries
were retrospectively reviewed of patients who were diagnosed
with RCM based on the criteria proposed by Schulman
et al12,13 (Table 1) and who had received BoNT-A treatment
(BOTOX; Allergan Inc., Irvine, CA, USA) between June 2008
and April 2012.
Of note, the available abortive medications for migraine in
Taiwan are oral dihydroergotamine (DHE) and oral or intra-
nasal triptans; other formulations of triptan and parenteral
DHE, the use of which is proposed in the criteria for RCM, are
not available.2.3. Treatment paradigmBoNT-Awas administered to our patients in 21 or 31 fixed-
site, fixed-dose (FSFD) injections. Patients received either
single injection or a series of injections depending on their
ability and wishes. The protocol used from June 2008 to July
2010 was 100 U or 75 U BoNT-A at 21 sites, whereas the
FSFD protocol used from August 2010 (155 U BoNT-A at 31
sites) followed the injection paradigm of the Phase III
Research Evaluating Migraine Prophylaxis Therapy (PRE-
EMPT) studies.16e18 In both treatment paradigms, BoNT-A
was administered across several head and neck muscles. All
patients received FSFD injections at two corrugator, one
procerus, four frontalis, eight temporalis, and six occipitalis
sites; those for whom the PREEMPT paradigm was followed
received additional injections at four cervical paraspinal and
six trapezius sites.16e18 The concurrent use of headache pre-
ventive medications and/or acute abortive treatment was not
prohibited during the BoNT-A injection treatment period.2.4. Clinical informationPatients’ medical records, headache questionnaires, and
headache diaries were analyzed to obtain information about
demographics, Beck depression inventory (BDI) scores,19
body mass index (BMI),20 and headache profiles including
CM duration, concurrent use of headache preventive medica-
tions, overuse of abortive medications (MO), headache
directionality, ocular-type headache, adverse events (AEs),
injection dosage, headache frequency, and migraine disability
assessment score (MIDAS).21,22
Headache diaries maintained by patients within 28 days
prior to BoNT-A injection were used as a baseline. At base-
line, if the patients took abortive medication such as analgesics
and nonsteroidal anti-inflammatory drugs for 15 days/month,
and mixed drugs (triptans, ergotamines, opioids, and nonste-
roidal anti-inflammatory drugs) for 10 days/month, they were
classified as patients with MO.23 The injection day was
labeled Day 0, and changes in headache frequency and
MIDAS at 12 weeks were calculated. Headache frequency was
defined as a calendar day when the patient reported 4
continuous hours of headache diary episode. The MIDAS was
used to assess headache-related disabilities, classified using
Table 2
Patient demographics and headache profiles.
Total (n ¼ 94) Range
General
Female 79 (84.0) d
Age (y) 47.6  13.6 20e85
CM duration (y) 8.1  8.3 1e40
BDI score 15.0  9.4 0e38
BMI (kg/m2) 23.5  4.1 15.1e36.5
Medication overuse 18 (19.1) d
Headache characteristics
Baseline headache frequency (d/28 d) 23.9  8.1 8e30
Baseline MIDAS (median) 60.0 0e270
Headache directionality
Exploding 50 (53.2) d
Imploding 25 (26.6) d
Equal 19 (20.2) d
Ocular-type headache 31 (33.0) d
Number of preventive agents used at baseline
Single preventive agent 20 (21.3) d
Two preventive agents 48 (51.0) d
Three preventive agents 22 (23.4) d
Four preventive agents 4 (4.3) d
Data are presented as n (%) or mean  SD, unless otherwise indicated.
CM ¼ chronic migraine; BDI ¼ beck depression inventory; BMI ¼ body mass
index; MIDAS ¼ migraine disability assessment score, Taiwanese version.
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minimal or infrequent disability; Grade II, total score 6e10,
mild or infrequent disability; Grade III, total score 11e20,
moderate disability; and Grade IV, total score 21, severe
disability.22,24 Patients with 30% reduction in headache
frequency from baseline at 12 weeks were categorized as re-
sponders, and other patients were classified as nonresponders.
Patients’ demographics, BDI score, BMI, and some head-
ache profiles including MO,25 injection dosage, headache
directionality26,27 (see below), and ocular-type headache were
used to predict treatment response. In contrast to other
studies,26,27 our classification of headache directionality
included only imploding, exploding, and equal-type headaches;
the presence or absence of ocular-type headache was further
discriminated in our patients from headache directionality.
To determine headache directionality, we asked patients to
report whether their headaches were predominantly imploding
or exploding.26,27 An exploding headache was described as a
buildup of pressure inside the head, and an imploding head-
ache was described as the sensation of the head being crushed,
clamped, or stubbed by external forces.26 Patients with similar
frequencies of imploding and exploding headaches were
assigned to the equal-type headache group. Patients were also
classified according to the occurrence of ocular-type headache
by reporting whether they experienced eye-popping pain
during 50% of headaches (ocular-type group); patients who
experienced such pain during <50% of headaches were
assigned to the noneocular-type group.2.5. Statistical analysisStatistical analyses were performed using SPSS software
(PASW, version 18.0 for Windows; SPSS Inc., Chicago, IL,
USA). Paired and Student t tests were used to compare
continuous data with normal distributions in two related and
independent groups, respectively. The ManneWhitney U test
was used for continuous data without normal distributions.
The Chi-square test or Fisher’s exact test was used for cate-
gorical data. The McNemar test was used to evaluate changes
in paired binominal attributes. A two-sided test with p < 0.05
was considered to be statistically significant.
3. Results3.1. ParticipantsThe records of 110 patients with RCM who received BoNT-
A injections during the study periodwere reviewed.A total of 16
patients were excluded due to incomplete headache question-
naires (n ¼ 9) or administration of <75 U BoNT-A (n ¼ 7).
Ninety-four patients (15men, 79women;mean age, 47.6 13.6
years) were thus included in the analyses. The average CM
duration was 8.1 8.2 years, the mean BDI score was 15.0, and
the mean BMI was 23.5. About 20% of patients showed MO
while receiving BoNT-A injection treatment (Table 2). The
distributions of headache directionality and ocular-type head-
ache are listed in Table 2. The initial protocol (100 U or 75 U at21 sites; 100 U, n ¼ 59; 75 U, n ¼ 8) was used for 67 (71.3%)
patients, and the PREEMPT FSFD paradigm (155 U at 31 sites)
was used for 27 (28.7%) patients.
Four kinds of prophylactic agents were mainly used in our
patients on Day 0, including b-blocker (propranolol), calcium
channel blocker (flunarizine), antiepileptics (topiramate, val-
proate) and antidepressants (amitriptyline, venlafaxine,
duloxetine). Most patients received combination therapy, and
the frequencies of different combinations were: single
(21.3%), two (51.0%), three (23.4%), and four preventive
agents (4.3%; Table 2).3.2. Clinical profilesThe baseline headache frequency was 23.9  8.1 days/28
days. At 12 weeks, the frequency of headaches decreased to
17.4  11.0 days/28 days, representing a mean reduction from
baseline of 6.5  8.9 days ( p < 0.001).
The median MIDAS prior to injection was 60.0 (range,
0e270), with 19.1% of patients classified as Grade I (score
0e5), 4.3% each as Grade II (score 6e10) and Grade III (score
11e20), and 72.3% classified as Grade IV (score 21). At 12
weeks, the median MIDAS was 30.0 (range, 0e270) with
26.6% of patients classified as Grade I, 10.6% as Grade II,
7.4% as Grade III, and 55.3% as Grade IV. The improvement
in the median MIDAS was significant (baseline vs. 12 weeks,
60.0 vs. 30.0; p < 0.001).3.3. Predictors of treatment responseAmong 94 enrolled patients, 37 (39.4%) fit the criteria of
responders at 12 weeks after BoNT-A injection. The
Table 4
Adverse events according to botulinum toxin type A injection dosage.
155 U
n ¼ 27
100 U
n ¼ 59
75 U
n ¼ 8
Total
n ¼ 94
All adverse effects 9 (33.3) 17 (28.8) 1 (12.5) 27 (28.7)
Lateral eyebrow elevation 7 (25.9) 11 (18.6) 0 (0) 18 (19.1)
Neck soreness 2 (7.4) 3 (5.1) 0 (0) 5 (5.3)
Ptosis 0 (0) 3 (5.1) 1 (12.5) 4 (4.3)
Data are presented as n (%).
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MIDAS than the nonresponders (Table 3). However, no further
association was noted between responders and the different
combinations of preventive agents (Table 3). Thirty-one
(33.0%) patients had ocular-type headache (Table 2).
Compared with the nonocular type, patients with ocular-type
headache were more likely to be responders (ocular vs. non-
ocular, 54.8% vs. 31.7%; p ¼ 0.03; Table 3). However, the
mean reduction headache frequency did not differ significantly
between patients with and without ocular-type headache
(8.8  8.9 days and 5.5  8.4 days/28 days, p ¼ 0.089).
Headache directionality was not associated with treatment
response (Table 3). We also found no association between
treatment response and demographic or headache profile var-
iables, such as age, sex, MO, BDI score, or BMI 25 kg/m2.
Furthermore, BoNT-A dosage was not associated significantly
with treatment response, although the response rate was lowest
in patients receiving 75-U BoNT-A injections (155 U vs.
100 U vs. 75 U, 44.4% vs. 40.7% vs. 12.5%; p ¼ 0.280;
Table 3).3.4. Adverse eventsThere were 27 (28.7%) patients reported AEs (Table 4).
The most common AE was lateral eyebrow elevation (18 pa-
tients, 19.1%), followed by neck soreness (5 patients, 5.3%)
and ptosis (4 patients, 4.3%). The occurrence of AEs did not
differ significantly according to injection dosage (155 U vs.Table 3
Demographics and treatment and headaches profiles of responders and
nonresponders.
Total (n ¼ 94) p
Responders
(n ¼ 37)
Nonresponders
(n ¼ 57)
Mean age (y) 47.6  12.9 47.6  14.1 0.992
Female 29 (78.4) 50 (87.7) 0.227
Medication overuse 7 (18.9) 11 (19.3) 0.964
BDI score 14.7  8.9 15.2  9.7 0.931
BMI 25 7 (18.9) 20 (35.1) 0.091
50% reduction of MIDAS 25 (67.6) 11 (19.3) <0.001*
Number of preventive agents 0.289
Single preventive agent (n ¼ 20) 11 (29.7) 9 (15.8)
Two preventive agents (n ¼ 48) 15 (40.6) 33 (57.9)
Three preventive agents (n ¼ 22) 9 (24.3) 13 (22.8)
Four preventive agents (n ¼ 4) 2 (5.4) 2 (3.5)
BoNT-A dosage 0.280
155 U (n ¼ 27) 12 (44.4) 15 (55.6)
100 U (n ¼ 59) 24 (40.7) 35 (59.3)
75 U (n ¼ 8) 1 (12.5) 7 (87.5)
Headache directionality 0.127
Exploding (n ¼ 50) 19 (38) 31 (62)
Imploding (n ¼ 25) 7 (28) 18 (72)
Equal (n ¼ 19) 11 (57.9) 8 (42.1)
Ocular-type headache 0.031*
Yes (n ¼ 31) 17 (54.8) 14 (45.2)
No (n ¼ 63) 20 (31.7) 43 (68.3)
Data are presented as n (%).
*p < 0.05.
BDI ¼ Beck Depression Inventory; BMI ¼ body mass index; BoNT-
A ¼ botulinum toxin type A; MIDAS ¼ migraine disability assessment score.100 U vs. 75 U, 33.3% vs. 28.8% vs. 12.5%; p ¼ 0.564). It
was observed that AEs resolved spontaneously within 1e2
months (49.5  18.5 days) with no sequelae.4. Discussion
Among 94 patients with RCM enrolled in our study, about
40% experienced 30% reduction in headache frequency,
with an average decrease of 6.5 headache days/28 days at 12
weeks. The median MIDAS also improved after treatment.
Patients with ocular-type headache showed a trend of greater
reduction in headache days than did those without such
headaches. The AEs were acceptable and self-limited.
Unlike most patients with CM who do not receive adequate
treatment,3 patients with RCM are defined as refractory to at
least 2-month regimens of optimal doses of preventive medi-
cation and abortive treatment.12 On receiving BoNT-A injec-
tion, 78.7% of our patients were on two or more kinds of
preventive agents. Despite adequate preventive treatment,
headache frequency remained high (23.9 days/28 days) in
patients in our study and 76.6% had MIDAS >10. These
factors indicate that our patients were highly disabled,
regardless of adequate preventive medication regimens.
Hence, this study provided a clinical observation of the pro-
phylactic efficacy of BoNT-A injection for RCM.
Our study differs from the PREEMPT studies in several
ways. First, our patients fulfilled the criteria of RCM, rather
than only CM. Second, our patients were still on preventive
medications when receiving BoNT-A injection.16,17 Third, our
study had a retrospective open-label design, rather than being
a randomized control trial. Fourth, we used a primary outcome
timepoint of 12 weeks, rather than the 24 weeks used in the
PREEMPT studies. In the PREEMPT studies, reductions in
headache frequency from baseline were 8.4 days/28 days at 24
weeks and around 7.4 days at 12 weeks.28,29 The mean
headache frequency prior to treatment was higher in our study
than in the PREEMPT studies (23.9 vs.19.9 days/28 days), but
slightly less reduction in headache frequency was observed at
12 weeks after treatment (6.5 vs. 7.4 headache days/28
days).28,29
The incidence rates of AEs in our patients were similar to
those reported in the PREEMPT studies28 (all AEs, 28.7% vs.
29.4%; Table 4), and were not associated with injection
dosage. The PREEMPT studies reported eyelid ptosis in 3.6%
of patients receiving a total dose of 35 U BoNT-A to the
frontalis, corrugator, and procerus muscles,28 compared with
an incidence rate of 4.3% in our study in patients receiving
14 K.-H. Lin et al. / Journal of the Chinese Medical Association 77 (2014) 10e15similar BoNT-A doses (26e35 U) to these three muscles. Of
note, the frequency of lateral eyebrow elevation in our study
(19.1%) was relatively high among all AEs. Most AEs were
transient and subsided within 1e2 months. Overall, the AEs
observed in our study were acceptable, and we report no new
safety finding that would affect the known tolerability profile
of BoNT-A.28,30,31
Traditionally, central hypersensitivity is thought to play an
important role in CM.32 The mechanism of BoNT-A for CM
prophylaxis is proposed to involve the inhibition of peripheral
trigeminal sensory fiber sensitization, which in turn modulates
the activity of central trigeminal neurons and thus indirectly
leads to the inhibition of migraine headache.33,34 RCM may
have the same pathophysiology as CM, but further investiga-
tion is necessary to resolve this issue. Previous studies found
that some headache characteristics, such as ocular type,
imploding directionality, and aura, predicted the response to
BoNT-A injection.26,27,35 However, not all patients enrolled in
those studies had CM, and the findings might not be gener-
alizable to patients with CM. For patients with RCM, our
study showed that only ocular-type headache was associated
with a higher response rate to BoNT-A. Other predictors of
treatment response, such as headache directionality, MO, BDI
score, age, sex, injection dosage, and BMI 25, had no sig-
nificant association with treatment response (Table 3). Of note,
the small number of patients receiving 75-U BoNT-A in-
jections might have increased the risk of false-negative find-
ings when analyzing the relationship between injection dosage
and response. In fact, the response rate was nominally lower in
these patients than in those receiving higher doses (155 U vs.
100 U vs. 75 U, 44.4% vs. 40.7% vs. 12.5%). This finding
corresponded with those of previous studies that 100 U
BoNT-A is more likely to be effective for migraine
prophylaxis.18,36
Our study had several limitations. First, it was a retro-
spective chart review including patients treated with different
BoNT-A injection paradigms, and no placebo group was
included for comparison. Second, we used the modified RCM
criteria12,13 because intranasal or injectable DHE and inject-
able triptans are not available in Taiwan. Third, the measure-
ment of headache directionality used in our headache
questionnaire was not completely the same as used in previous
studies, and we should be cautious to extrapolate our study
results when compared to other studies. Fourth, a large pro-
portion of patients with RCM sought adjunctive therapies such
as Chinese herbs or acupuncture prior to receiving BoNT-A
injection, because the current NHI system in Taiwan does
not cover the costs of BoNT-A injection treatment. This
sociodemographic issue may alter patients’ willingness to
receive BoNT-A injection, and may have caused selection bias
in our study. Hence, additional studies comparing the cost
effectiveness of BoNT-A and other treatment modalities are
needed, including consideration of the cost of healthcare
resource utilization, health-related quality of life, and loss of
productivity, especially in patients with RCM.
In conclusion, about 40% of patients with RCM achieved
30% reduction in headache frequency at 12 weeks after BoNT-A injection. AEs were generally acceptable. Additionally,
patients with ocular-type headache were more likely to
respond to this treatment.Acknowledgments
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